HUTCHMED (China) (CHIX:HCML) Other Current Receivables: £13.7 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:HCML HUTCHMED (China) Ltd CHIX:HCML
60 GF Score
Price £1.67
GF Value £2.24
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is HUTCHMED (China) Other Current Receivables?

HUTCHMED (China) CHIX:HCML 60 Other Current Receivables is £13.7 Mil as of Dec. 2025. GuruFocus rates CHIX:HCML with a GF Score™ of 60/100 and a GF Value™ of £2.24 (Modestly Undervalued). The stock has 8 warning signs investors should review.

HUTCHMED (China)'s Other Current Receivables for the quarter that ended in Dec. 2025 was £13.7 Mil.

HUTCHMED (China)'s quarterly Other Current Receivables declined from Dec. 2024 (£9.66 Mil) to Jun. 2025 (£0.00 Mil) but then increased from Jun. 2025 (£0.00 Mil) to Dec. 2025 (£13.66 Mil).

HUTCHMED (China)'s annual Other Current Receivables declined from Dec. 2023 (£26.08 Mil) to Dec. 2024 (£9.66 Mil) but then increased from Dec. 2024 (£9.66 Mil) to Dec. 2025 (£13.66 Mil).

HUTCHMED (China) Other Current Receivables Related Terms

HUTCHMED (China) Other Current Receivables Historical Data

* Premium members only.

The historical data trend for HUTCHMED (China)'s Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HUTCHMED (China) Other Current Receivables Chart

HUTCHMED (China) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.88 23.96 26.08 9.66 13.66

HUTCHMED (China) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.08 26.68 9.66 0.00 13.66
CHIX:HCML
60GF Score
HUTCHMED (China) Ltd CHIX:HCML
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HUTCHMED (China) Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of £13.7 Mil mean?
HUTCHMED (China) (CHIX:HCML) has a Other Current Receivables of £13.7 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on HUTCHMED (China) and its competitors.
Is HUTCHMED (China)'s Other Current Receivables too high?
HUTCHMED (China)'s current Other Current Receivables is £13.7 Mil. Overall, HUTCHMED (China) has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s Other Current Receivables compare to ZTS and UTHR?
HUTCHMED (China)'s Other Current Receivables of £13.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on HUTCHMED (China) and its competitors. HUTCHMED (China)'s current Other Current Receivables is £13.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
Based on GuruFocus' analysis, HUTCHMED (China) (CHIX:HCML) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.24, compared to a current price of £1.67 — trading 25.4% below its estimated fair value. The current Other Current Receivables is £13.7 Mil. HUTCHMED (China)'s overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For HUTCHMED (China) (CHIX:HCML), the current Other Current Receivables is £13.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HUTCHMED (China) (CHIX:HCML) Overvalued in 2026?

Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued. The current stock price of £1.67 is trading 25.4% below its estimated GF Value™ of £2.24. GuruFocus considers HUTCHMED (China) to be Modestly Undervalued.

Key valuation signals for CHIX:HCML:

  • Other Current Receivables: £13.7 Mil
  • GF Value™: £2.24 vs. price of £1.67 (25.4% below fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the CHIX:HCML stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HUTCHMED (China) Business Description

Address 2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
60GF Score

Get the complete analysis for CHIX:HCML

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.67
Price
£2.24
GF Value